Cure My Disease

Don't miss your cure!

 Log in / Sign up

What drives choice of artificial pancreas? survey reveals patient priorities

NCT ID NCT07177404

Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study surveyed 166 adults with type 1 diabetes to understand what factors influence their choice of hybrid closed-loop (artificial pancreas) systems. Participants included those already using, waiting to start, or considering such technology. The goal was to learn what matters most to patients when selecting a system that automatically adjusts insulin delivery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

166 people

The number who actually took part.

Started

Sep 2025

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be approached via their usual University Hospitals of Derby \& Burton NHS diabetes care team.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: ≥18 years (no upper age limit) * Type 1 diabetes (any duration) * People who use closed-loop therapy or wait to start closed-loop therapy or considering closed-loop therapy in the future * Ability to give informed consent Exclusion Criteria: * Any other type of diabetes apart from type 1 diabetes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabete mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabete mellitus Type 1 diabetes mellitus

Contacts and locations

Locations

  • University Hospitals of Derby and Burton

    Derby, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.